Patritumab deruxtecan (HER3-DXd; MK-1022) is an investigational HER3-directed antibody-drug conjugate composed of a human immunoglobulin G1 monoclonal antibody to HER3 (patritumab) covalently linked ...

Vani Pathuri holds a academic foundation in healthcare and business, beginning with a nursing degree from Owaisi College of ...

Of 320 eligible patients approached between January 2021 and July 2022, 239 patients completed the QuIC questionnaires after informed consent discussion for biomarker (n = 128) or therapeutic (n = 111 ...

Vera Therapeutics jumped by 67.49 percent on Monday to close at $31.74 apiece following the success of its pivotal ORIGIN Phase […] We recently published a list of These 10 Stocks Blew Past ...

Oral nicotine pouches may have potential for smoking cessation, but scientific evidence on the effects of pouches and their constituents on smoking behaviour is limited. Design This study was a 4-week ...

Mirati Therapeutics is the subject of takeover speculation in the biopharma sector once again, as it waits for the FDA's decision on its KRAS inhibitor adagrasib in non-small cell lung cancer (NSCLC).

After months of speculation about a possible takeover of Mirati Therapeutics, Bristol-Myers Squibb has reached a deal to buy the company and its KRAS inhibitor Krazati in a deal valued at up to $5 ...

Enliven Therapeutics, Inc. (NASDAQ:ELVN) is among the best NASDAQ stocks under $50 to buy. On Monday, analysts at Goldman Sachs started coverage on Enliven Therapeutics, Inc.

Travere Therapeutics, Inc. (NASDAQ:TVTX) is among the 10 Best Growth Stocks Under $100 to Buy Now. HC Wainwright & Co., a leading investment bank, has initiated a “Buy” rating for Travere ...

Eli Lilly & Co. agreed to buy Verve Therapeutics Inc., a US biotech that’s seeking to use gene editing to prevent clogged arteries, for as much as $1.3 billion.

View today's Turning Point Therapeutics Inc stock price and latest TPTX news and analysis. Create real-time notifications to follow any changes in the live stock price.

Tango Therapeutics, Inc. remains a high-risk, high-reward biotech, focused on PRMT5 inhibitors for MTAP-deleted cancers—a large, underserved market opportunity. Disappointing clinical data last ...